Barchart.com
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.2500 -0.0800 (-6.02%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.2800 +0.0300 (+2.40%) 16:23 ET
Quote Overview for Fri, Apr 25th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Day Low
1.2350
Day High
1.3300
Open 1.3300
Previous Close 1.3300 1.3300
Volume 293,400 293,400
Avg Vol 501,080 501,080
Stochastic %K 70.90% 70.90%
Weighted Alpha -52.60 -52.60
5-Day Change +0.0500 (+4.17%) +0.0500 (+4.17%)
52-Week Range 0.8900 - 4.2900 0.8900 - 4.2900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
 Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,507
  • Shares Outstanding, K 42,511
  • Annual Sales, $ 53,480 K
  • Annual Income, $ -84,690 K
  • EBIT $ -94 M
  • EBITDA $ -97 M
  • 60-Month Beta 0.91
  • Price/Sales 0.99
  • Price/Cash Flow N/A
  • Price/Book 0.35

Options Overview Details

View History
  • Implied Volatility 301.18% ( +54.82%)
  • Historical Volatility 83.62%
  • IV Percentile 78%
  • IV Rank 43.54%
  • IV High 676.25% on 04/17/25
  • IV Low 12.00% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 44
  • Volume Avg (30-Day) 72
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 881
  • Open Int (30-Day) 785

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 1
  • High Estimate -0.65
  • Low Estimate -0.65
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -316.67%
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.
Get delivered to your inbox for FREE:
Sign Up.

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8900 +40.45%
on 04/14/25
Period Open: 1.0300
1.4495 -13.76%
on 04/23/25
+0.2200 (+21.36%)
since 03/25/25
3-Month
0.8900 +40.45%
on 04/14/25
Period Open: 1.2200
1.4495 -13.76%
on 04/23/25
+0.0300 (+2.46%)
since 01/24/25
52-Week
0.8900 +40.45%
on 04/14/25
Period Open: 3.1500
4.2900 -70.86%
on 07/19/24
-1.9000 (-60.32%)
since 04/25/24

Most Recent Stories

More News
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options Newswire.ca - Mon Dec 23, 2024

/CNW/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...

ONCY : 0.5562 (-4.65%)
RPTX : 1.2500 (-6.02%)
IMRX : 1.4500 (-0.68%)
ONC.TO : 0.77 (-4.94%)
RNXT : 0.9900 (-1.98%)
CRGX : 4.51 (-0.33%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector BayStreet.ca - Thu Dec 19, 2024

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.5562 (-4.65%)
PYXS : 1.0600 (-2.75%)
RPTX : 1.2500 (-6.02%)
IMRX : 1.4500 (-0.68%)
CVM : 0.2904 (-2.06%)
ONC.TO : 0.77 (-4.94%)
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Newswire.ca - Tue Jul 16, 2024

/CNW/ - Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early...

RPTX : 1.2500 (-6.02%)
Amplitude Ventures Closes $263 Million Precision Medicine Venture Fund Newswire.ca - Tue May 28, 2024

/CNW/ - Amplitude Ventures, a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI, today announced...

RPTX : 1.2500 (-6.02%)
Wall Street Thinks This Cathie Wood Stock Could Jump by 187% Motley Fool - Wed Aug 16, 2023

This small-cap biotech stock holds enormous growth potential.

SHOP : 97.12 (+2.10%)
ROKU : 65.71 (+1.64%)
TSLA : 284.95 (+9.80%)
RPTX : 1.2500 (-6.02%)
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors Business Wire - Fri Apr 28, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board...

RPTX : 1.2500 (-6.02%)
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting Business Wire - Tue Apr 18, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical...

RPTX : 1.2500 (-6.02%)
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306 Business Wire - Tue Mar 14, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib...

RPTX : 1.2500 (-6.02%)
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results Business Wire - Tue Feb 28, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended...

RPTX : 1.2500 (-6.02%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX PR Newswire - Mon Feb 13, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...

RPTX : 1.2500 (-6.02%)
SecureWorks: Fiscal Q2 Earnings Snapshot AP - Thu Sep 7, 2023

SecureWorks: Fiscal Q2 Earnings Snapshot

SCWX : 8.51 (+0.24%)
Secureworks® Announces Second Quarter Fiscal 2024 Results PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Secureworks® (NASDAQ: SCWX), a global leader in cybersecurity, today announced financial results for its second quarter, which ended on August...

SCWX : 8.51 (+0.24%)
Secureworks to Report Second Quarter Fiscal 2024 Financial Results on September 7, 2023 PR Newswire - Thu Aug 17, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX) today announced that it plans to release its second quarter fiscal 2024 financial results on Thursday, September 7,...

SCWX : 8.51 (+0.24%)
SecureWorks: Fiscal Q1 Earnings Snapshot AP - Thu Jun 8, 2023

SecureWorks: Fiscal Q1 Earnings Snapshot

SCWX : 8.51 (+0.24%)
Secureworks Unifies Industrial Cybersecurity with the First Integrated MDR Solution for OT and IT PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Secureworks® (NASDAQ: SCWX), a global leader in cybersecurity, today announced two new offerings to unify the way industrial organizations...

SCWX : 8.51 (+0.24%)
Secureworks to Report First Quarter Fiscal 2024 Financial Results on June 8, 2023 PR Newswire - Thu May 18, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX) today announced that it plans to release its first quarter fiscal 2024 financial results on Thursday, June 8, 2023,...

SCWX : 8.51 (+0.24%)
SecureWorks: Fiscal Q4 Earnings Snapshot AP - Thu Mar 23, 2023

SecureWorks: Fiscal Q4 Earnings Snapshot

SCWX : 8.51 (+0.24%)
Secureworks Reports 120% Growth in Annual Taegis Revenue to $188 Million in Connection with Fourth Quarter and Full Year Fiscal 2023 Results PR Newswire - Thu Mar 23, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX), a global leader in cybersecurity, today announced financial results for its fourth quarter and full fiscal year,...

SCWX : 8.51 (+0.24%)
Secureworks to Report Fourth Quarter and Full Year Fiscal 2023 Financial Results on March 23, 2023 PR Newswire - Mon Feb 27, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX) today announced that it plans to release its fourth quarter and full year fiscal 2023 financial results on Thursday,...

SCWX : 8.51 (+0.24%)
Secureworks to Participate in Upcoming Needham Growth Conference PR Newswire - Thu Jan 5, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX), a global leader in cybersecurity, today announced that it is scheduled to present at the 25th Annual Needham Growth...

SCWX : 8.51 (+0.24%)
SecureWorks: Fiscal Q2 Earnings Snapshot AP - Thu Sep 7, 2023

SecureWorks: Fiscal Q2 Earnings Snapshot

SCWX : 8.51 (+0.24%)
Secureworks® Announces Second Quarter Fiscal 2024 Results PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Secureworks® (NASDAQ: SCWX), a global leader in cybersecurity, today announced financial results for its second quarter, which ended on August...

SCWX : 8.51 (+0.24%)
Secureworks to Report Second Quarter Fiscal 2024 Financial Results on September 7, 2023 PR Newswire - Thu Aug 17, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX) today announced that it plans to release its second quarter fiscal 2024 financial results on Thursday, September 7,...

SCWX : 8.51 (+0.24%)
SecureWorks: Fiscal Q1 Earnings Snapshot AP - Thu Jun 8, 2023

SecureWorks: Fiscal Q1 Earnings Snapshot

SCWX : 8.51 (+0.24%)
Secureworks Unifies Industrial Cybersecurity with the First Integrated MDR Solution for OT and IT PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Secureworks® (NASDAQ: SCWX), a global leader in cybersecurity, today announced two new offerings to unify the way industrial organizations...

SCWX : 8.51 (+0.24%)
Secureworks to Report First Quarter Fiscal 2024 Financial Results on June 8, 2023 PR Newswire - Thu May 18, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX) today announced that it plans to release its first quarter fiscal 2024 financial results on Thursday, June 8, 2023,...

SCWX : 8.51 (+0.24%)
SecureWorks: Fiscal Q4 Earnings Snapshot AP - Thu Mar 23, 2023

SecureWorks: Fiscal Q4 Earnings Snapshot

SCWX : 8.51 (+0.24%)
Secureworks Reports 120% Growth in Annual Taegis Revenue to $188 Million in Connection with Fourth Quarter and Full Year Fiscal 2023 Results PR Newswire - Thu Mar 23, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX), a global leader in cybersecurity, today announced financial results for its fourth quarter and full fiscal year,...

SCWX : 8.51 (+0.24%)
Secureworks to Report Fourth Quarter and Full Year Fiscal 2023 Financial Results on March 23, 2023 PR Newswire - Mon Feb 27, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX) today announced that it plans to release its fourth quarter and full year fiscal 2023 financial results on Thursday,...

SCWX : 8.51 (+0.24%)
Secureworks to Participate in Upcoming Needham Growth Conference PR Newswire - Thu Jan 5, 2023

/PRNewswire/ -- Secureworks (NASDAQ: SCWX), a global leader in cybersecurity, today announced that it is scheduled to present at the 25th Annual Needham Growth...

SCWX : 8.51 (+0.24%)
More news for this symbol

Business Summary

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare...

See More

RPTX Related ETFs

Managed Assets
Percent
Symbol %Holdings 3M %Chg
RPTX +2.46%
Repare Therapeutics Inc
VHT 0% -5.62%
Healthcare ETF Vanguard
GWX 0% +5.23%
S&P Smallcap Intl SPDR
Symbol %Holdings 3M %Chg
RPTX +2.46%
Repare Therapeutics Inc
GWX 0% +5.23%
S&P Smallcap Intl SPDR
VHT 0% -5.62%
Healthcare ETF Vanguard

RPTX Related stocks

Symbol Last 3M %Chg
RPTX 1.2500 +2.46%
Repare Therapeutics Inc
AZN 69.57 +0.74%
Astrazeneca Plc ADR
AMGN 280.84 +1.97%
Amgen Inc
GILD 103.17 +10.85%
Gilead Sciences Inc
VRTX 493.84 +12.33%
Vertex Pharmaceutic
BMY 47.90 -19.73%
Bristol-Myers Squibb Company

Compare Symbols

Key Turning Points

Daily
52-Week
3rd Resistance Point 1.4033
2nd Resistance Point 1.3667
1st Resistance Point 1.3083
Last Price 1.2500
1st Support Level 1.2133
2nd Support Level 1.1767
3rd Support Level 1.1183

See More

52-Week High 4.2900
Fibonacci 61.8% 2.9912
Fibonacci 50% 2.5900
Fibonacci 38.2% 2.1888
Last Price 1.2500
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective
Wed, Apr 30, 2025 5:00 PM UTC
Reserve Your Spot